Phase Forward Central Coding™ First to Achieve Uppsala Monitoring Center Certification
14 6월 2010 - 9:00PM
Business Wire
Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, today
announced its Central Coding™ application has become the first
product to achieve certification by the Uppsala Monitoring Center
(UMC). Launched today (“Uppsala Monitoring Centre Launches Software
Certification Program for WHO Drug Dictionary Enhanced”), UMC’s new
certification is designed to help software developers quickly and
easily integrate the WHO Drug Dictionary Enhanced. The WHO Drug
Dictionary Enhanced is the world’s most comprehensive dictionary of
medicinal product information and the de facto standard for coding
concomitant medication in clinical trials and adverse event
reporting.
Optimized to work with InForm™ Global Trial Management (GTM) and
other Phase Forward solutions, Central Coding is a configurable,
multilingual, Web-based coding and dictionary management
application designed to automate the coding process and minimize
the manual effort required to code verbatim terms. The Central
Coding application successfully passed the 24 use cases and
associated acceptance criteria included in the UMC certification
process, designed to indicate that vendor implementation processes
are accurate.
The certification announced today also offers software
developers free training and a software development kit, including
documentation and example programs. UMC is demonstrating the
features of the new certification program at the Drug Information
Association’s 46th Annual Meeting in Washington, D.C., which began
yesterday and runs through this Thursday, June 17.
“UMC certification is a rigorous undertaking, and Phase Forward
completed the process impressively, clearly benefiting from their
WHO Dictionary integration expertise and experience with the
Central Coding product,” said Ola Strandberg, Vendor Liaison
Officer at UMC. “Having achieved certification, Phase Forward
Central Coding offers users a product that has demonstrated full
utilization of the Dictionary’s constantly evolving feature
set.”
“UMC has devised a useful certification process to help
organizations like ours achieve integration with the WHO Drug
Dictionary Enhanced,” said Martin Young, Phase Forward Senior Vice
President, Integration and Product Strategy. “In working closely
together on this certification we had ample opportunity to observe
the commitment of the UMC team. We congratulate them on the formal
launch today, and are proud to concurrently announce our position
as the first vendor to achieve the certification.”
More information about the Software Certification Program is
available at http://www.umc-products.com/certification.
About the Uppsala Monitoring Centre
The Uppsala Monitoring Centre (UMC) provides tools and resources
to enhance clinical trials and drug safety operations, ranging from
international monitoring of drug safety data to lexicon products
and advanced tools for data analysis. Our main products are:
- The WHO Drug Dictionary Enhanced
is the world’s most comprehensive dictionary of medicinal product
information and de-facto standard for coding concomitant medication
in clinical trials and adverse event reporting.
- VigiBase™ – the WHO adverse drug
reaction database, which is the world’s largest and most
comprehensive resource of international drug safety data.
As a centre of scientific excellence, UMC has extensive
experience of database administration and data mining complex sets
of clinical data. To advance this work, UMC has developed a range
of products and techniques for companies and organizations working
with life sciences.
About Phase Forward
Phase Forward is a leading provider of integrated data
management solutions for clinical trials and drug safety. Phase
Forward’s products and services have been utilized in over 10,000
clinical trials involving more than 1,000,000 clinical trial study
participants at over 300 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber
Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and
Healthcare Products Regulatory Agency. Additional information about
Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. This press release
contains express or implied forward-looking statements relating to,
among other things, the continued interoperability and integration
of Phase Forward's products with third-party offerings, the
benefits to customers from such interoperability and integration,
the continued ability of Phase Forward’s products to meet the
certification requirements of third parties and the performance and
acceptance of Phase Forward’s products. These statements are
neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond Phase Forward's
control, which could cause actual results to differ materially from
those contemplated in these forward-looking statements. In
particular, the risks and uncertainties include, among other
things, Phase Forward's inability to convince current and potential
customers to order its products and services, the failure of
customers to realize benefits from the interoperability and
integration of Phase Forward’s and third-party offerings, changes
in the technical specifications of Phase Forward’s products or
third-party offerings and the ability of Phase Forward to maintain
the certification requirements of third parties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. Phase Forward undertakes no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise. For additional disclosure regarding these and other
risks faced by Phase Forward, see the disclosure contained in Phase
Forward's public filings with the Securities and Exchange
Commission including, without limitation, its most recent Annual
Report on Form 10-K and its most recent Quarterly Report on Form
10-Q.
Phase Forward (NASDAQ:PFWD)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Phase Forward (NASDAQ:PFWD)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
